Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02297698
Title Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Acronym HER3+
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Cancer Insight, LLC
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.